Form 4: X4 Pharmaceuticals CEO Paula Ragan Sells Shares to Cover Tax Obligations

Paula Ragan, CEO of X4 Pharmaceuticals, sold 49,678 shares of common stock on March 11, 2024, to cover personal income tax obligations related to the settlement of a restricted stock unit award.

Summary

• On March 11, 2024, Paula Ragan, the President and CEO of X4 Pharmaceuticals, sold 49,678 shares of the company's common stock.
• The sale was executed at a weighted average price of $0.8828 per share, with individual transactions ranging from $0.863 to $0.9147.
• The total number of shares beneficially owned by Ms. Ragan following the transaction is 765,068.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 24, 2023.
• The purpose of the sale was to cover personal income tax obligations arising from the settlement of a restricted stock unit award.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Insider sales are a common occurrence, especially to cover tax obligations related to equity compensation. The use of a pre-arranged Rule 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a common practice for covering tax obligations.
• The sale is unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates